EP0122833A1 - Heterogeneous assay method for antigenic biological substances using antibody-hybrid conjugates, and reagent therefor - Google Patents

Abstract

1. Claims (for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE) Heterogeneous phase assay method for antigenic substances, which consists in : a) reacting the sample containing the substance to be assayed with an antibody (or an antigen) immobilized on an insoluble matrix, b) bringing the matrix, which has reacted according to a), into contact with a coupling product composed of an antibody (or antigen) to the substance to be assayed and an anti-enzyme antibody bridged via symmetrical molecules chosen from benzoquinone and glutaraldehyde, which molecules are bound to them covalently, c) then reacting the enzyme corresponding to the antibody which composes the coupling product, and d) assaying the enzyme bound to the matrix modified during the stages a) to c). 1. Claims (for the Contracting State AT) Heterogeneous phase assay method for antigenic substances, which consists in : a) reacting the sample containing the substance to be assayed with an antibody (or an antigen) immobilized on an insoluble matrix, b) bringing the matrix, which has reacted according to a), into contact with a coupling product composed of an antibody (or antigen) to the substance to be assayed and an anti-enzyme antibody bridged via symmetrical molecules chosen from benzoquinone and glutaraldehyde, which molecules are bound to them covalently, c) then reacting the enzyme corresponding to the antibody which composes the coupling product, and d) assaying the enzyme bound to the matrix modified during the stages a) to c).

Description

The present invention relates to a heterogeneous phase assay method of antigenic biological substances using hybrid antibody derivatives, such as conjugates prepared by coupling of anti-immunoglobulin antibodies and anti-enzyme antibodies and the reagents for its production.

Immunochemical assay methods are known, in which an antibody directed against the substance to be assayed is fixed on a matrix, and an enzyme is used as a marker which can be assayed by conventional techniques, said enzyme being covalently linked to a directed antibody. against the substance to be dosed. This process is described for example by S. AVRAMEAS, J.L. GUESDON in "Solid phase enzyme immuno-assays" published in "Applied Biochemistry and Bio-engineering Academic Press Editeur, 1981, 73, 471-482". However, the preparation of the product resulting from the coupling of the antibody and the enzyme is delicate and the enzyme is frequently partially denatured during this reaction.

A heterogeneous phase assay method is also known in which the substance to be assayed is fixed on an excess of immobilized antigen in order to then react a lectin / immobilized antigen or lectin / substance to be assayed product before revealing the lectin fixed by a compound carrying glycosidic fractions; such a process is described in European patent application -A-0 041 426.

We have now found a new method for the measurement of antigenic biological substances, in heterogeneous phase, and with enzymatic marker using a new coupler intermediate product which is the result of the covalent coupling of two antibodies, one directed against the substance to be assayed. , the other directed against an enzyme which is chosen as the marker of the system and will be revealed by conventional techniques. The invention also relates to this new product and to the reagent system necessary for carrying out the process.

The method for assaying antigenic biological substances according to the invention consists in 1) bringing the medium containing the substance to be assayed into contact with an antibody of said substance fixed on a solid matrix, insoluble in the biological medium containing the substance, separating the matrix modified on which the antibody and the substance to be assayed are fixed; 2) reacting said modified matrix with an intermediate coupler product having simultaneously an affinity for the substance to be assayed and for an enzyme, said product resulting from the covalent attachment of two antibodies, one of which is directed against the substance to be assayed and the another against the enzyme, then separate the reacted matrix; 3) bringing the isolated or non-isolated enzyme into contact with the matrix thus treated during a so-called labeling step, then separating the matrix thus treated; 4) assay the fixed enzyme, during a so-called revelation step by measuring the enzymatic activity of the treated matrix brought into contact with a solution of the enzyme substrate. This method is also applicable to the assay of antibodies. In this case, the antigen is fixed on the matrix.

During its assay, the enzyme will therefore be attached to the matrix via an "antibody-antigen" complex, itself linked non-covalently to the intermediate product composed of an antibody linked to another antibody by through a bridge fixed by covalent bonds.

A variant of the assay method according to the invention consists, during the second step, in reacting the modified matrix with a mixture prepared beforehand of the intermediate coupling product and of the chosen enzyme.

The method according to the invention is suitable for assaying any biological substance for which antibodies can be prepared and in particular antigens, antibodies, haptens, immunoglobulins, proteins, hormones. The enzymes which can be used as markers are of plant or bacterial or animal origin and whether or not purified, and soluble or fixed on particles such as particles with a diameter of between approximately 0.5 and 20 μ, such as latex microbeads. These microbeads can fix proteins as indicated by SINGER, PLOTZ, Am. J. Med., (1956), 21, 888.

One of the advantages of the invention resides in the fact that the enzymes used as markers do not need to be purified, which obviously simplifies the process and makes it less expensive.

The intermediate coupler product which results from the coupling of two antibodies via covalently linked molecules, one of the antibodies being directed against an enzyme is another subject of the invention.

The antibodies used to prepare the intermediate coupler product according to the invention are advantageously monoclonal antibodies prepared as described in "Nature (1975) 256, 495 by K5hler and Milstein.

Polyclonal anti-enzyme antibodies can also be used, and are prepared according to known methods (J.L. GUESDON Handbook of Experimental Immunology, ed. D.M. WEIR, Blackwell Scientific Publication, 1973).

The results obtained during their application to the assays are equivalent to those obtained with the monoclonal antibodies, if the state of purity of the polyclonal antibodies is sufficient.

Antibody coupling is mainly carried out according to a process the principle of which is described by S. AVRAMEAS in Immunochemistry 6, 43 (1969), that is to say by the action of glutaraldehyde to create a bridge fixed by covalent bond to the two antibodies . Antibodies can also be coupled by benzoquinone, or any other functional reagent capable of covalently binding to proteins and which would not modify the immunological activity of the two antibodies. The two antibodies which will be coupled need not originate from animals of the same breed, which is another advantage of the invention. On the other hand, the product resulting from the coupling must be soluble in the aqueous solutions commonly used in this type of biological assay, and the conditions of the preparation are chosen accordingly. According to a preferred preparation process, in a phosphate buffer at a pH close to 7, a certain amount is dissolved. quantity of the antibody directed against the antigenic substance to be assayed, such as an anti-IgE or an anti-IgG, to obtain a solution containing from 20 to 100 mg / 100 ml. Then added from 1 to 10 times the weight of the first antibody, of an anti-enzyme antibody, and then a 1% aqueous solution of glutaraldehyde, so that the final mixture contains a concentration of glutaraldehyde of between 0.02% at 0.5% (final concentration). The incubation time of the mixture at a temperature of about 37 ° C is a function of the relative concentrations of the three compounds; it can be from half an hour to more than five hours. The bridging reaction is then stopped by adding glycine (final concentration 0.1 M).

If necessary, the coupler product can then be isolated by methods known to those skilled in the art.

The method according to the invention makes it possible to dose small quantities of substances, since a reliable result is already obtained when the concentration of the antigenic substance in the medium is approximately 1 ng / ml if it is a protein antigen and 5 at 10ng / ml if it is an antibody. It is also more precise than the previous methods using an enzyme directly linked to an antibody, the amplifying power of the system according to the invention being greater than that of the systems previously described.

The enzyme used, which allows the revelation can be of bacterial, animal or vegetable origin; it suffices that there is a reaction _/ to reveal it, of safe and easy implementation.

Said enzyme will for example have a fluorogenic or chromogenic substrate; or can be fixed on insoluble particles with a diameter of between 0.5 and 20 microns approximately.

• - un anticorps ou antigène de la substance à doser immobilisé sur une matrice insoluble
• - un produit coupleur résultant du pontage covalent entre un antigène ou anticorps de la substance à doser et un anticorps anti-enzyme
• - ladite enzyme
• - un système révélateur de ladite enzyme

Another object of the invention is the kit of reagents which allows the implementation of the method according to the invention and which contains:

• - an antibody or antigen of the substance to be measured immobilized on an insoluble matrix
• - a coupler product resulting from the covalent bridging between an antigen or antibody of the substance to be measured and an anti-enzyme antibody
• - said enzyme
• - a system revealing said enzyme

The following non-limiting examples illustrate the invention.

The matrices are wells or wells, formed in commercial microplates consisting of a product on which the antibody of the substance to be assayed can be immobilized; such a product can be polystyrene, on which the fixing of the antibody is carried out by a process known per se, and for example by contact with a buffered solution of the antibody for a few hours at 37 ° C. and then for 1 day around 4 ° C. Plates with microgodets in U or V are sold by exampleGREINER in France

The present invention also relates to matrices consisting of a magnetic support or not such as Magnogel (R) (Pharm-industry) prepared according to patent FR-A-2,334,106, or of polyacrylamide or agarose or any another substance to immobilize a biological reagent.

Anti-human IgE or anti-oxidase (black radish) sheep immunosera and E. coli anti-β-D-galactosidase rabbit immunosera used can be obtained by hyperimmunizing animals with the corresponding proteins mixed with complete Freund's adjuvant (product sold by Difco-Detroit USA Laboratories) as described in Immunochemistry 6, 43-53 (1969).

Polyclonal antibodies directed against human IgE or peroxidase can be isolated from these immunosera by affinity chromatography with immunoadsorbents prepared with Ultrogel ( ^R ) (Trademark of Pharm-Industry) as described in J. Immunol. Meth 11, 129 (1976). The polyclonal antibodies directed against β-galactosidase can be isolated from the immunoserum by chromatography on DEAE cellulose as described in Proc. Soc. Exp. Med. Biol. 103, 250 (1960).

The anti-peroxidase and anti-β-galactosidase monoclonal antibodies can be prepared for example according to the technique described by Kôhler and Milstein in Nature 256 495 (1975).

The measurement of the enzymatic activity of the matrix having undergone the various stages of the process, makes it possible to determine the quantity of enzyme fixed to the matrix by means of the various products (antigen or immobilized antibody, substance in doses, hybrid antibody conjugate -antibody), and can be carried out in a conventional manner, by putting the enzyme in the presence of a suitable solution of its substrate; we deduce the amount of fixed substance to be dosed and therefore that of departure.

For example, for β-galactosidase, 0.2 ml of a 0.1 M aqueous phosphate buffer solution is introduced into the well of the microplate. at pH 7 (M being put for mole / liter) containing 2.67 mM of o-nitrophenylgalactopyranoside, 0.1M of β-mercaptoethanol, 1mM of magnesium sulfate, 0.2 mM of manganese sulfate and 2mM of Titriplex (product sold by the Merck Company, Darmstadt-RFA). The plate is then incubated in the dark at 37 ° C; this incubation can last from 1 to 4 hours and an arbitrary duration is chosen within these limits. At the end of the incubation, the enzyme is inactivated by adding 50 μl of 2M sodium carbonate and measuring the absorption of light by the resulting solution at a wavelength of 414 nm.

For peroxidase, for example, 0.2 ml of an aqueous solution of pH 4.8 containing 4 mg / ml of o-phenylenediamine and 0.06% (by weight) of hydrogen peroxide is introduced into the cup. buffered with 0.05 M sodium citrate solution. The plates are incubated for 10 minutes in the dark at 37 ° C. The enzymatic reaction is then stopped by adding 50 μl of 3N HCl to the well. The absorption is read at 492 nm.

When the mixture consisting of the hybrid antibody-antibody conjugate and the enzyme serving as the selected developer is reacted with the modified matrix, that is to say on which the substance to be assayed has been fixed by means of its antigen (or its antibody), this mixture is carried out for example in a phosphate buffer solution without modification of the quantities of antibody and enzyme used compared to those of the successive reactions.

EXAMPLE 1 Determination of human IgE immunoglobulins in human serum

A - Preparation of reagents

• On introduit dans 0,9 ml de tampon phosphate 0,1M, à pH 6,8, 0,5 mg d'anticorps de mouton anti-IgE humaines et 2 à 4 mg d'anticorps monoclonaux anti-β-galactosidase, ou 1 à 2 mg d'anticorps polyclonaux anti-β-galactosidase, puis sous agitation douce 0,1 ml d'une solution aqueuse a 1 g/100 ml de glutaraldéhyde. Le mélange réactionnel est laissé 2 heures à température ambiante. Une autre variante consiste à ajouter 0,1 ml de solution à 5 % de glutaraldéhyde et à ne laisser incuber qu'une demi-heure. Ensuite, 50µl d'une solution aqueuse 2M de glycine sont ajoutés. Le mélange réactionnel est alors laissé 2 heures à température ambiante avant centrifugation et dialyse une nuit à 4°C contre du tampon phosphate (PBS) ; on le mélange ensuite avec un même volume de glycérol bidistillé. La solution peut être ainsi conservée à -20°C pendant plusieurs mois jusqu'à son emploi.
• B - Dosage

In this example, the result of the coupling reaction with glutaraldehyde of the anti-human IgE antibody with anti-β-galactosidase / E.coli antibody carried out as follows is used as an intermediate product:

• Is introduced into 0.9 ml of 0.1M phosphate buffer, at pH 6.8, 0.5 mg of anti-human IgE sheep antibody and 2 to 4 mg of anti-β-galactosidase monoclonal antibodies, or 1 with 2 mg of anti-β-galactosidase polyclonal antibodies, then with gentle stirring 0.1 ml of an aqueous solution containing 1 g / 100 ml of glutaraldehyde. The reaction mixture is left for 2 hours at room temperature. Another variant consists in adding 0.1 ml of 5% glutaraldehyde solution and incubating for only half an hour. Then, 50 μl of a 2M aqueous glycine solution are added. The reaction mixture is then left for 2 hours at room temperature before centrifugation and dialysis overnight at 4 ° C. against phosphate buffer (PBS); it is then mixed with the same volume of double-distilled glycerol. The solution can thus be stored at -20 ° C for several months until it is used.
• B - Dosage

The wells of a polystyrene plate are covered with anti-human IgE sheep antibodies: 0.1 ml of a 0.1M sodium carbonate solution (pH = 9.6) containing 0.1 μg is introduced into each of anti-IgE antibodies, the plate is incubated for 2 hours at 37 ° C, then 15 hours at 4 ° C and washed. Then 0.1 ml of the serum to be studied, suitably diluted, is introduced into each well thus covered and the plate incubated for 18 hours at 4 ° C.

(The serum to be studied is diluted before dosing by adding a phosphate buffered saline solution containing 0.1 g / 100 ml of TWEEN-20 ( ^R ) (esters of polyethoxylated fatty acids and sorbitol, supplier Merck) and 0 , 3 g / 100 ml of gelatin so that the concentration of human IgE to be assayed is between approximately 100 IU / ml and 0.2 IU / ml).

After the end of the incubation, the plate is washed 3 times with a phosphate buffered saline solution containing 0.1 g / 100 ml of TWEEN-20 and then. a solution of the coupling product of the two antibodies previously prepared is added to each well, said solution being diluted if necessary so that the concentration of coupled anti-IgE is approximately 5 μg / ml.

After a two-hour incubation at 37 ° C., the plate is again washed three times and 0.1 ml of a solution containing approximately 50 μg / ml of the enzyme chosen as a marker, that is to say β -galactosidase is added to each well and the plate is left to incubate for 2 hours. After the usual washes, 0.2 ml of a solution of the β-galactosidase substrate, prepared as described above, are added and the revelation is carried out according to a conventional method.

In Figure 1 is shown the absorption of the final solution, read at 414 nm as a function of the IgE concentration of the human serum to be studied, expressed in IU / ml. This concentration was determined beforehand for comparison purposes, by a standard immunoenzymatic method, using a standardized reference serum, as described in J. Allergy Clin. Immunol. 61 23 (1978). The relationship between absorption and IgE concentration is a function of the coupling product between the two antibodies. Curve 1 corresponds to the IgE assay using a hybrid conjugate prepared by coupling 0.5 mg of anti-human IgE sheep antibodies with 1 mg of anti-β-galactosidase monoclonal antibodies; for curve 2, 0.5 mg of human anti-IgE antibodies were used with 4 mg of monoclonal anti-β-galactosidase antibodies and for curve 3, 0.5 mg and 8 mg were used respectively.

EXAMPLE 2 Other assay of human IgE immunoglobulins in human serum

In this example, the marker enzyme is peroxidase extracted from black radish, type I (purity index: 0.6). The intermediate product resulting from the glutaraldehyde coupling of the anti-IgE antibody with the anti-peroxidase antibody is prepared by following the procedure described in Example 1, reacting 0.5 mg of anti sheep antibody -IgE with 2 mg of anti-peroxidase antibodies.

Figure 2 provides a graphical representation of the absorption ultimately measured by the concentration of serum IgE studied, expri _- Mee in international units per ml. (IU / ml). Curve 1 was obtained with mouse monoclonal antibodies, curve 2 with sheep polyclonal antibodies. In addition, this method was applied to the determination of different sera containing known concentrations of IgE and using lots of purity peroxidase variables. The results obtained are shown in Table 1. It can be seen that the minimum concentration of IgE detectable by this method is independent of the state of purity of the enzyme: 0.4 to 0.8 international units of IgE are assayed. per ml, whether the peroxidase preparation used is very purified (purity index: 3.0) or crude (purity index: 0.57).

EXAMPLE 3 Simplified determination of IgE in human serum

A product prepared as in Example 2, in solution in phosphate buffer, is used as hybrid conjugate. 0.1 ml of this solution is mixed with 0.1 ml of the peroxidase solution (50) lg / ml) and this mixture is introduced into the wells on the walls of which the anti-IgE antibody has been fixed beforehand and then the serum to be studied, as described in Example 1. After an incubation of two hours, the plate is washed and the revelation is carried out in a conventional manner.

The assay is faster, since a step and an incubation are omitted, however the method is a little less sensitive than that described in Example 2, as shown in Figure 3. Curve 1 was plotted using the method described in Example 2, curve 2 in Example 3.

EXAMPLE 4 Determination of the anti-Echinococcus granulosus antibody in human serum

An antigen extracted from Echinococcus granulosus prepared from the liquid of the cysts of sheep infected with the virus is fixed in the wells of a polystyrene microtiter plate. parasite.

The fixation is carried out by leaving in the microgodets for 2 hours at 37 ° C. and then 18 hours at 4 ° C., 0.1 ml of phosphate buffer solution containing 1 μg of antigen. The plate is then washed three times with phosphate buffer containing 0.1% of TWEEN-20 and then 0.1 ml of the human serum to be studied, diluted suitably, are introduced into each well. The dilution of the serum between 1/200 and 1 / 204,800 approximately, is carried out with phosphate buffer containing 0.1% of TWEEN-20 and 0.3% of gelatin.

The covered plate is incubated for 2 hours at 37 ° C. and washed three times, then 0.1 ml of the solution is added to each well, to 5 μg / ml of the coupling product of the two antibodies; the plate is then kept for 2 hours at 37 ° C. before three successive washes with the same buffered solution as above.

The coupling product between the anti-human IgG antibody and the anti-β-galactosidase antibody used was prepared with glutaraldehyde using the method described in Example 1: 0.5 mg of anti-antibody was used - Human IgG, 4 mg of anti-enzyme antibodies and 0.1 ml of a 1% solution of glutaraldehyde for a total volume of 1 ml

The revelation of the β-galactosidase is EFFEC _- killed as described in Example 1.

The results obtained by this process have been compared with those obtained using a known immunoenzymatic assay, using an anti-IgG antibody labeled with phosphatase, the latter is prepared by reaction of 5 mg of rabbit antibody anti-human IgG with 10 mg of alkaline phosphatase from E. coli in the presence of glutaraldehyde, as described in Immunochem. 6 43-53 (1969).

Instead of adding the coupling product of the two antibodies according to the invention to the wells, 0.1 ml of a 5 μg / ml solution of the antibody labeled with the enzyme resulting from the coupling reaction is added. . The plate is left for 2 hours at 37 ° C before / washing several times; the revelation step is then carried out by adding 0.2 ml of a 1 M NaCl solution containing 0.1 M of Tris / HCl buffer (ph = 8) and 1 mM of p-nitrophenol phosphate; after 16 hours at 37 ° C., the enzymatic reaction is stopped by adding 50 μl of K ₂ HPO ₄ 3M to each well and the light absorption, due to p-nitrophenol, is measured at 405 nm.

Table II gives the results of this comparative study. It can be seen that the process according to the invention is much more sensitive.

Claims (22)

1. Immunological coupler product composed of an antibody or antigen, directed against an antigenic substance and of a monoclonal or polyclonal anti-enzyme antibody bridged by means of a bifunctional molecule which is / is covalently linked to them. 2. Product according to claim 1, characterized in that the enzyme is chosen. Among β-galactosidase from E. coli, peroxidase and phosphatase. 3. Product according to one of claims 1 or 2, characterized in that the antigenic substance is an immunoglobulin. 4. Product according to any one of the preceding claims, characterized in that the bifunctional molecule used for the bridging is glutaraldehyde. 5. Method for assaying, in heterogeneous phase, antigenic substances, characterized in that it consists: a) immobilizing an antibody or an antigen of the substance to be assayed on an insoluble matrix, b) to fix the substance to be assayed on its antibody or antigen, c) bringing the matrix reacted according to b) into contact with an intermediate coupler product according to claim 1, soluble, having simultaneously an antigenic affinity for the substance to be assayed and for an enzyme, d) bringing the enzyme, isolated or not, into contact with the matrix thus modified to mark it, e) assaying the fixed enzyme, by measuring the enzymatic activity of the matrix modified in the preceding steps. 6. Method according to claim 5, characterized in that steps c) and d) are carried out simultaneously by contacting the matrix on which the substance to be assayed is fixed, with a mixture of the coupler product and the corresponding enzyme. 7. Method according to one of claims 5 or 6, characterized in that the coupler product results from buffering between a compound having an antigenic affinity for the substance to be measured and an anti-enzyme antibody by the action of glutaraldehyde. 8. Method according to one of claims 5 to 7, characterized in that the enzyme used for labeling has a chromogenic or fluorigenic substrate. 9. Method according to any one of claims 5 to 8, characterized in that the enzyme is fixed on insoluble micro particles. 10. Method according to any one of claims 5 to 9, characterized in that the enzyme is chosen from β-galactosidase from E.coli and peroxidase. 11. Method according to any one of claims 5 to 10, characterized in that the substance to be assayed is an antigen or an antibody. 12. Method according to any one of claims 5 to 10, characterized in that the substance to be assayed is an immunoglobulin. Soluble coupler 13. Product for the implementation of the assay method according to claim 7, characterized in that it results from the bypass _r E- action of glutaraldehyde on a mixture of anti-immunoglobulin antibody and anti-enzyme, chosen from 'aati-β-galactosidase and anti-peroxidase. 14. Kit of reagents for assaying the antigenic substances by applying the method according to any one of claims 5 to 13, characterized in that it comprises: - an antibody or antigen of the substance to be assayed, immobilized on an insoluble matrix, - a coupler product resulting from a bridging between an antigen, or an antibody, of the substance to be assayed and an anti-enzyme antibody, - the enzyme - a system of compounds to reveal the enzyme. 1. Method for assaying, in heterogeneous phase, antigenic substances, characterized in that it consists in: a) immobilizing an antibody, or an antigen, of the substance to be assayed on an insoluble matrix, b) to fix the substance to be assayed on its antibody, or its antigen, c) bringing the matrix reacted in step b) into contact with a coupler product, soluble, having simultaneously an affinity for the substance to be assayed and for an enzyme d) bringing the enzyme into contact with the matrix thus modified to mark it, e) assaying the fixed enzyme by measuring the enzymatic activity of the matrix modified by the preceding steps. 2. Assay method according to claim 1, characterized in that the coupler product results from the bridging of an antibody or antigen of the substance to be assayed and of an anti-monoclonal or polyclonal anti-enzyme antibody by a bifunctional molecule covalently linked. 3. Method according to one of claims 1 or 2, characterized in that steps c) and d) are carried out simultaneously by bringing the matrix onto which the substance to be dosed is attached, with a mixture of the coupler product and the corresponding enzyme. 4. Assay method according to any one of claims 1 to 3, characterized in that the coupler product results from the action of glutaraldehyde on the mixture of the antibody, or antigen of the substance to be assayed, and the anti-enzyme antibodies. 5. Method according to one of claims 1 to 4, characterized in that the enzyme used for labeling has a chromogenic or fluorigenic substrate. 6. Method according to any one of claims 1 to 5, characterized in that the enzyme is fixed on insoluble micro particles. 7. Method according to any one of the claims 1 to 6, characterized in that the enzyme is chosen from galactosidase, from E.coli and peroxidase. 8. Method according to any one of claims 1 to 7, characterized in that the substance to be assayed is an immunoglobulin.

Images